Genome Editing Verification

With the development of CRISPR/Cas9 system, genome editing has become efficient and programmable, leading to promising translational studies and clinical trials for both genetic and non-genetic diseases. However, a major concern in the applications of the CRISPR/Cas9 system is its off-target effects, namely the deposition of unexpected, unwanted, or even adverse alterations to the genome. Analysis of off-target editing is an important aspect of the development of safe nuclease-based genome editing therapeutics. RedyBio offers efficient, and economical assay to profile and verify off-target genome editing.